

Supplementary Table 1. Demographic parameters, comorbidities, clinical features

	Group A n=418	Group B n=1082	P value	Clinical Features (n=418)	n (%)	Treatment received	
Median age (years) (Q1, Q3)	34 (28,43)	35 (29,48)	0.048	Fever	300 (71.8)		
<40 years, n (%)	286 (68.4)	640 (59)	0.001	Cough	142 (34)	Antimicrobials	
≥40 years, n (%)	132 (31.6)	442 (41)		Rhinitis	108 (25.8)		
Males/Females	258/160	770/312	<0.001	Sore throat	99 (23.7)	Doxycycline	209
				Weakness	96 (23)	Ivermectin	202
				Only weakness [†]	1 (0.2)	Azithromycin	185
				Malaise	21 (5)	Beta lactams	20
				Body ache	82 (19.6)	Favipiravir	15
				Only body ache [†]	1 (0.2)	Remdesivir	11
				Anosmia	58 (13.9)	Metronidazole	4
				Headache	57 (13.6)	DEC	1
				Only headache [†]	1 (0.2)	Linezolid	1
				Dyspnoea	34 (8.1)		
				Myalgia	31 (7.4)		
				Only myalgia [†]	1 (0.2)	Supportive	
BMI (Kg/m ²) Mean ± SD	25 ±3.45	24.76 ± 3.63	0.31	Diarrhoea	24 (5.7)	Anticoagulants	
				Loss of taste	21 (5)	LMWH	9
BMI ≥ 25, n (%)	205 (49)	473 (43.7)	0.06	Tachycardia	17 (4.1)	Oral factor Xa inhibitors	5
Diabetes mellitus, n (%)	40 (9.6)	102 (9.4)	0.93	Chest discomfort	14 (3.3)		
Hypertension, n (%)	45 (10.8)	125 (11.6)	0.66	Anorexia	5 (1.2)	Antiplatelets	6
On RAAS blockers [#]	29 (6.9)	75 (6.9)	0.99	Backache	7 (1.7)		
Heart disease, n (%)	6 (1.4)	17 (1.6)	0.85	Only backache [†]	1 (0.2)	Others:	
				Altered taste	6 (1.4)	Antihistaminic	42
						Antiarrhythmic	1
						Ayurvedic	10
				Blood pressure changes	11 (2.6)	Only Ayurvedic	3
				Increase in BP	9 (2.1)	Baclofen	1
				Low BP	1 (0.2)	Aripiprazole	1
				Fluctuating BP	1 (0.2)		
Lung disease, n (%)	13 (3.1)	29 (2.7)	0.65	Eye symptoms	9 (2.1)	Post COVID-19 complaints in n=45 (10.7%**)	
Hypothyroidism, n (%)	20 (4.8)	34 (3.1)	0.13	Burning sensation in eyes	3 (0.7)	Weakness	20 (44.4 ^{##})
Pre-vaccination history of COVID-19, n (%)	51 (12.2)	153 (14.1)	0.33	Watery eyes	2 (0.5)	Cough	8 (17.8)
Two dose recipients, n (%)	382 (91.4) *	1047 (96.8)	<0.001	Redness in eyes	2 (0.5)	Dyspnoea	6 (13.3)
Only one dose recipient	36 (8.6)	35 (3.2)		Pain in eyes	1 (0.2)	Backache	3 (6.7)
Number of symptoms (range)	1-9	NA		Conjunctivitis (diagnosed)	1 (0.2)	Bodyache	3 (6.7)
Median number of symptoms (Q1, Q3)	3 (2-4)					Chest discomfort	3 (6.7)
TTR range in days	1-75			Others		Headache	3 (6.7)
Median TTR, Days (Q1, Q3)	7 (4,13)			Nausea/vomiting	8 (1.9)	Anosmia	1 (2.2)
				Abdominal discomfort	7 (1.7)	Hyposmia	1 (2.2)
				Anxiety/uneasiness	4 (0.9)	Diarrhoea	1 (2.2)
				Weight loss	4 (0.9)	Difficulty in recalling names	1 (2.2)
				Rash	3 (0.7)	Dryness of nose	1 (2.2)
				Only rash [†]	1 (0.2)	Eye symptoms	1 (2.2)
				Tachypnoea	3 (0.7)	Fever	1 (2.2)
				Dry mouth	3 (0.7)	Hypertension	1 (2.2)
				Dry throat	4 (0.9)	Itching in hands	1 (2.2)

				Dizziness	3 (0.7)	Joint pain	1 (2.2)
				Insomnia	3 (0.7)	Loss of taste	1 (2.2)
				Joint pain	2 (0.5)	Rheumatoid arthritis	1 (2.2)
				Neck pain	2 (0.5)	aggravated	
				Increased thirst	2 (0.5)	Shivering	1 (2.2)
				Shivering	2 (0.5)	Sleep disturbance	1 (2.2)
				Palpitations	2 (0.5)	Sore throat	1 (2.2)
				Constipation	1 (0.2)	Syncope	1 (2.2)
				Bloating	1 (0.2)	Tachycardia	1 (2.2)
				Increased appetite	1 (0.2)	Thrombocytopenia	1 (2.2)
				Increased craving for sweet food	1 (0.2)	Tremors on standing	1 (2.2)
				Lymph node swelling	1 (0.2)		
				Burning sensation in urine	1 (0.2)		
				Hiccups	1 (0.2)		
				Jaundice	1 (0.2)		
				Syncope	1 (0.2)		
				Drowsiness	1 (0.2)		
				Atrial fibrillation (in patient of CHF)	1 (0.2)		
				Difficulty in talking	1 (0.2)		
				Oral ulcer	1 (0.2)		
				Itching	1 (0.2)		
				Wheeze	1 (0.2)		
				Atypical behaviour	1 (0.2)		
				Tingling sensation in body	1 (0.2)		
				Only tingling sensation [¶]	1 (0.2)		

[* Of 418 in Group A, 388 received two doses, six of them developed COVID-19 before receiving the second dose

[#]Included ACEI or ARBs or both

[¶]RT-PCR confirmed case

**Out of all vaccinees developing COVID-19; ^{##}All individual post-COVID-19 complaint percentages are out of individuals developing post-COVID-19 complaints, n=45

Abbreviations: BMI: body mass index, COVID-19: Corona virus disease-2019, DEC: diethylcarbamazine, LMWH: low molecular weight heparin, RAAS: renin angiotensin aldosterone system]

Supplementary Table 2: Bivariate analysis to determine risk factors of severity of disease in individuals developing COVID-19 (n=418)

	Asymptomatic-mild COVID-19, n=371	Moderate-severe COVID-19, n=47	P value
Median age (years, (Q1, Q3))	33 (28,42)	37 (28.5,49.5)	0.055
Age-categories			
< 40 years	258 (69.5)	28 (59.6)	0.16
≥ 40 years	113 (30.5)	19 (40.4)	
Sex (Female/Male)	151/220	9/38	0.004
Co-morbidities			
BMI (Kg/m²) categories			
≥25	178 (48)	27 (57.4)	0.22
<25	193 (52)	20 (42.6)	
DM, n (%)	32 (8.6)	8 (17)	0.06
HTN, n (%)	37 (10)	8 (17)	0.14
RAAS blockers, n (%)	22 (5.9)	7 (14.9)	0.023
Heart disease, n (%)	4 (1.1)	2 (4.3)	0.084
Lung disease, n (%)	9 (2.4)	4 (8.5)	0.024
Hypothyroidism, n (%)	18 (4.9)	2 (4.3)	0.86
Two dose recipients, n (%)	345 (93)	37 (78.7)	0.001
Pre-vaccination history of COVID-19, n (%)			
	43 (11.6)	8 (17)	0.28

[BMI: body mass index, COVID-19: Corona virus disease-2019, DM: diabetes mellitus, HTN: hypertension, RAAS: renin angiotensin aldosterone system]

Supplementary Table 3: Binomial logistic regression analysis showing association between severity of COVID-19 and potential risk factors including use of RAAS blockers

Tentative risk factors (n=418)	OR (CI)	P value
Sex		
Male	2.9 (1.36-6.6)	0.006
Female (reference)		
Age (years)		
≥40	1.1 (0.5-2.3)	0.86
<40 (reference)		
BMI (Kg/m²)		
≥25	1.4 (0.74-2.7)	0.3
<25 (reference)		
Diabetes mellitus		
Yes	1.25 (0.45-3.6)	0.66
No (reference)		
Heart disease		
Yes	1.6 (0.24-11.5)	0.61
No (reference)		
Lung disease		
Yes	3.3 (0.87-12.3)	0.08
No (reference)		
Use of RAAS blockers#		
Yes	2.1 (0.7-6.2)	0.18
No (reference)		
Number of doses of vaccine		
1	2.8 (1.14-6.8)	0.025
2 (reference)		

[#Significant correlation ($r>0.7$) was seen between hypertension and use of RAAS blockers with variance inflation factor value of >2.5 . To exclude multi-collinearity, hypertension was excluded from this analysis.

BMI: body mass index, CI: confidence interval, RAAS: renin angiotensin aldosterone system, OR: Odds ratio]